Multiple Sclerosis (MS) Clinical Trials

Find Multiple Sclerosis (MS) Clinical Trials Near You

Relationship Between Single- and Dual-Task Obstacle Crossing Performance and Fatigue and Disability Levels in Patients With Relapsing-Remitting Multiple Sclerosis

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

This cross-sectional observational study aims to investigate the relationship between obstacle crossing performance under single-task and dual-task conditions and the levels of fatigue and disability in individuals with Relapsing-Remitting Multiple Sclerosis (RRMS). Walking performance will be assessed under standard walking and obstacle crossing conditions with and without a concurrent cognitive task. The study will examine how increased task complexity affects walking performance and its association with fatigue, disability, cognition, and functional mobility.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Age between 18 and 65 years.

• Diagnosis of Multiple Sclerosis according to the 2017 McDonald criteria.

• Diagnosis of Relapsing-Remitting Multiple Sclerosis.

• Expanded Disability Status Scale (EDSS) score between 0 and 6.

• Clinically stable disease during the previous 6 months.

• Montreal Cognitive Assessment (MoCA) score of 26 or higher.

• Able to speak and understand Turkish.

• Able to provide written informed consent.

Locations
Other Locations
Turkey
Afyonkarahisar Health Sciences University
RECRUITING
Afyonkarahisar
Contact Information
Primary
Yunus Emre Kundakcı, Assoc. Prof.
y.emre.kndkc@gmail.com
+90 272 246 28 34|
Time Frame
Start Date: 2026-03-20
Estimated Completion Date: 2027-02-20
Participants
Target number of participants: 30
Treatments
Relapsing-Remitting Multiple Sclerosis
Adults aged 18 to 65 years with a diagnosis of Relapsing-Remitting Multiple Sclerosis (RRMS) according to the 2017 McDonald criteria, an Expanded Disability Status Scale (EDSS) score between 0 and 6, a Montreal Cognitive Assessment (MoCA) score of 26 or higher, and a clinically stable disease course during the previous 6 months. Participants will undergo observational assessments of walking, obstacle crossing performance, fatigue, cognition, functional mobility, and fear of movement. No intervention will be administered.
Related Therapeutic Areas
Sponsors
Leads: Afyonkarahisar Health Sciences University

This content was sourced from clinicaltrials.gov